Company: NDRA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001654954-25-009643
Chunk: 18

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 18
---
 purchase price of each share of common stock and accompanying Series Warrants was $227.50 and the purchase price of each pre-funded warrant and accompanying Series Warrants was $227.325. Warrant Exercises On May 2, 2023, the Company conducted a registered offering in which the Company issued 1,232 warrants to purchase shares of common stock for an exercise price per share equal to $2,450. The warrants expire May 2, 2028. In December 2023, the Board approved a temporary reduction of the exercise price per share from $2,450 to $1,225. The Company also issued to the underwriter and its designees warrants exercisable for an aggregate of 172 shares of common stock for an exercise price per share equal to $2,625. The warrants expire November 2, 2026. During the six months ended June 30, 2025, no warrants were exercised. The following table summarizes all warrant activity of the Company for the six months ended June 30, 2025:     Weighted  Weighted     Average  Average   Number of  Exercise  Contractual   Warrants  Price  Term (Years) Balance outstanding at December 31, 2024  180,707  $85.38   4.58 Granted  -   -   - Exercised  -   -   - Forfeited  -   -   - Expired  -   -   - Balance outstanding at June 30, 2025  180,707  $85.38   4.09 Exercisable at June 30, 2025  180,707  $85.38   4.09  Common Stock Warrants As described above in this Note 9, the Company issued 178,255 Series A Warrants and 178,255 Series B Warrants. In 2024, most of the Series B warrants were exercised. The Company accounts for these warrants, in the aggregate, in accordance with the guidance in ASC 815 “Derivative and Hedging” whereby under that provision the warrants do not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, the Company classified the warrant instruments as a liability at fair value and adjusts the instruments to fair value each period. This liability